National Accreditation Board for Testing and Calibration Laboratories

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 1 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
Permanent Facility				
1	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Bacillus Calmette Guerin Vaccine (freeze dried)	Virulent Mycobacteria Test	IP 2018 Vol III; Page 3594
2	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Bacillus Calmette Guerin Vaccine (Freeze Dried)	Physical Aspect Test	CDL/WI/003
3	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Bacillus Calmette Guerin Vaccine (Freeze Dried)	Sterility	CDL/WI/041
4	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Bacillus Calmette Guerin Vaccine (Frreze Dried) I	Identity test	IP 2018 Vol III; Page 3594
5	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Bacillus Calmette- Guerin Vaccine (Freeze dried)	Skin Reactivity Test	IP 2018 Vol III; Page 3594
6	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Potency 'T' Component (by Antibody Induction Method)	IP 2018 Vol III; Page 3695-3696 Vol III; Page 3692-3693
7	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Identity test	IP 2018 Vol III; Page 3600 Vol I; Clause 2.2.14 Page 67-68 & 71-72
8	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Lime Flocculation	IP 2018 Vol I; Clause 2.2.16 Page 71-72
9	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Physical Aspect	CDL/WI/003
10	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Potency 'T' Component (by Lethal Challenge Method in G.Pigs)	IP 2018 Vol III; Page 3600 Vol III; Page 3695-3696
11	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Potency 'D' Component (by Antibody Induction method)	IP 2018 Vol III; Page 3600 Vol III; Page 3615 & 3598-3599
12	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus vaccine (adsorbed)	Potency 'D' Component (by Lethal Challenge method)	IP 2018 Vol III; Page 3600 Vol III; Page 3614-3615
13	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Potency 'T' component (by Lethal Challenge method in mice	IP 2018 Vol III; Page 3695-3696 Vol III; Page 3692-3693

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 2 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
14	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Specific Toxicity	IP 2018 Vol III; Page 3600
15	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed)	Sterility	CDL/WI/041
16	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed) For adults and adolescent	Limes Flocculation	IP 2018 Vol I; Clause 2.2.16 Page 71-72
17	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed) For adults and adolescents	Abnormal toxicity	IP 2018 Vol III; Page 3695-3696 Vol III; Page 3692-3693
18	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed) For adults and adolescents	Physical Aspect	CDL/WI/003
19	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed) For adults and adolescents	Potency 'T' Component (by Antibody Induction method)	IP 2018 Vol III; Page 3695-3696 Vol III; Page 3692-3693
20	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed) For adults and adolescents	Potency 'T' Component (by Lethal challenge method in G.Pigs)	IP2018 Vol III; Page 3602 Vol III; Page 3696-3697
21	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed) For adults and adolescents	Sterility	CDL/WI/041
22	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria & Tetanus Vaccine (adsorbed) For adults and Adolscents	Potency 'D' Component (by Lethal Challenge method)	IP 2018 Vol III; 3602 Vol III; Page 3614-3615
23	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Antitoxin	Physical Aspect Test	CDL/WI/003
24	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Antitoxin	Abnormal Toxicity Test	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
25	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Antitoxin	Identity	IP,2018 Page 3598-3599 & Clause 2.2.14 Page 67-69
26	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Antitoxin	Potency	IP,2018 Page 3062-63
27	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Antitoxin	Sterility	CDL/WI/041

SCOPE OF ACCREDITATION

Laboratory Name :	CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA		
Accreditation Standard	ISO/IEC 17025:2017		
Certificate Number	TC-5586	**Page No**	3 of 22
Validity	08/08/2021 to 07/08/2023	**Last Amended on**	18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
28	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus ,Pertussis (Whole Cell) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'T' Component (by Antibody Induction Method)	IP 2018 Vol III; Page 3695-3696 Vol III; Page 3692-3693
29	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus ,Pertussis (Whole Cell) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Sterility	CDL/WI/041
30	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Abnormal Toxicity	IP 2018 Vol III; Page 3603 Vol I; Clause 2.2.1 Page 27
31	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Identity Test	IP 2018 Vol III; Page 3603 Vol I; Clause 2.2.14 Page 67-68 & 71-72
32	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Limes Flocculation	IP 2018 Vol I; Clause 2.2.16 Page 71-72
33	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Physical Aspect Test	CDL/WI/003
34	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (Adsorbed)	Potency 'T' Component (by Lethal Challenge Method in G.Pigs)	IP 2018 Vol III; Page 3604 Vol III; Page 3695-3696
35	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Potency 'D' Component (by Antibody Induction method)	IP 2018 Vol III; Page 3600 Vol III; Page 3615 & 3598-3599
36	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Potency 'D' Component (by Lethal Challenge method)	IP 2018 Vol III; Page 3604 Vol III; Page 3614-3615
37	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Potency 'P' Component	IP 2018 Vol III; Page 3604 Vol III; Page 3664-3665
38	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and pertussis Vaccine (adsorbed)	Potency 'T' Component (by Antibody Induction method)	IP 2018 Vol III; Page 3604 Vol III; Page 3664-3665
39	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Potency 'T' Component (by Lethal challenge method in mice)	IP 2018 Vol III; Page 3604 Vol III; Page 3696-3697
40	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (Adsorbed)	Specific Toxicity for D & T Component	IP 2018 Vol III; Page 3603
41	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Pertussis Vaccine (adsorbed)	Sterility	CDL/WI/041

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 4 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
42	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus and Perussis Vaccine (Adsorbed)	Mouse weight Gain Test	IP 2018 Vol III; Page 3603
43	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus Pertussis (whole cell) and Hemophilus Type b Conjugate Vaccine (adsorbed)	Abnormal toxicity	IP 2018 Vol III; Page 3611 Vol I; Clause 2.2.1 Page 27
44	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus Pertussis (Whole cell) Hepatitis B (r DNA) and Haemophilus Type b Conjugate Vaccine (Adsorbed)	Abnormal toxicity test	IP2018 Vol III; Page 3606 Vol I; Clause 2.2.1 Page 27
45	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus pertussis (whole cell) and Haemophilus Type b conjugate Vaccine (adsorbed)	Mouse weight gain test	IP 2018 Vol III; Page 3607 Vol III; Page 3663-3664
46	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus pertussis (Whole cell) Hepatits B (r DNA) and Haemophilus Type b Conjugate Vaccine)	Specific toxicity	IP 2018 Vol III; Page 3607 Vol III; Page 3600
47	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis (Whole cell) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Identity test	IP 2018 Vol III; Page 3611 Vol I; Clause 2.2.14 Page 67-68 & 71-72
48	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis (Whole Cell) and Haemophilus Type b Conjugate Vaccine (Adsorbed)	Potency 'T' Component (by Lethal Challenge Method in G.Pigs)	IP 2018 Vol III; Page 3611 Vol III; Page 3695-3696
49	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis (Whole cell) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'D' Component (by Lethal Challenge Method)	IP 2018 Vol III; Page 3611 Vol III; Page 3614-3615
50	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Identity test	IP 2018 Vol III; Page 3606 Vol I; Clause 2.2.14 Page 67-68 & 71-72
51	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Limes Flocculation	IP 2018 Vol I; Clause 2.2.16 Page 71-72
52	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (Adsorbed)	Potency 'T' Component (by Lethal Challenge Method in G.Pigs)	IP 2018 Vol III; Page 3607 Vol III; Page 3695-3696
53	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'T' Component (by Lethal Challenge Method in Mice)	IP 2018 Vol III; Page 3607 Vol III; Page 3696-3697
54	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus, Pertussis(Whole Cell) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'T' Component (by Lethal Challenge Method in Mice)	IP 2018 Vol III; Page 3611 Vol III; Page 3696-3697
55	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Limes Flocculation	IP 2018 Vol I; Clause 2.2.16 Page 71-72

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 5 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
56	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) and Haemophilus Type b Conjugate Vaccine (Adsorbed)	Physical Aspect Test	CDL/WI/003
57	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'P' Component	IP 2018 Vol III; Page 3611 Vol III; Page 3664-3665
58	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Physical Aspect Test	CDL/WI/003
59	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'D' Component (by Antibody Induction Method)	IP 2018 Vol III; Page 3600 Vol III; Page 3615 & 3598-3599
60	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'D' Component (by Lethal Challenge Method)	IP 2018 Vol III; Page3607 Vol III; Page 3614-3615
61	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency Hepatitis B Component (by In-Vitro method)	IP 2018 Vol III; Page 3607 Vol III; Page 3627-3628
62	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Potency 'P' component	IP 2018 Vol III; Page 3607 Vol III; Page 3664-3665
63	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (Adsorbed)	Potency 'T' Component (by Antibody Induction Method)	IP 2018 Vol III; Page 3695-3696 Vol III; Page 3692-3693
64	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis (Whole Cell) Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (adsorbed)	Sterility	CDL/WI/041
65	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tetanus,Pertussis(Whole cell) and Haemophilus Type b conjugate Vaccine (adsorbed)	Potency 'D' Component (by Antibody Induction Method)	IP 2018 Vol III; Page 3600 Vol III; Page 3615 & 3598-3599
66	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria Tewtanus Pertussis (Whole cell) Hepatitis B (rDNA) and Haemophilus Type b conjugate vaccine (adsorbed)	Mouse weight gain test	IP 2018 Vol III; Page 3607 Vol III; Page 3663-3664
67	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria, and Tetanus Vaccine (Adsorbed) For adults and adolescents	Identification	IP 2018 Vol III; Page 3602 Vol I; Clause 2.2.14 Page 67-68 & 71-72
68	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Diphtheria, and Tetanus Vaccine (Adsorbed) For adults and adolescents	Specific Toxicity	IP 2018 Vol III; Page 3601
69	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Haemophilus Type B Conjugate Vaccine	Abnormal Toxicity	IP 2018 Vol III; Page 3624 Vol I; Clause 2.2.1 Page 27

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 6 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
70	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Haemophilus Type b Conjugate Vaccine	Physical Aspect Test	CDL/WI/003
71	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Haemophilus Type b Conjugate Vaccine	Sterility	CDL/WI/041
72	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Hepatitis B vaccine(rDNA)	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
73	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Hepatitis B vaccine(rDNA)	identity	IP,2018 Vol III; Page 3626-3628
74	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Hepatitis B vaccine(rDNA)	Physical Aspect Test	CDL/WI/003
75	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Hepatitis B vaccine(rDNA)	Potency	IP,2018 Vol III; Page 3626-3628
76	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Hepatitis B vaccine(rDNA)	sterility test	CDL/WI/041 &CDL/WI/042
77	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Surface Antigen)	Abnormal toxicity test	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
78	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Surface Antigen)	Identity test	IP,2018 Vol III; Page 3634-3636
79	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Surface Antigen)	Physical Aspect test	CDL/WI/003
80	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Surface Antigen)	Sterility Test	CDL/WI/041 & CDL/WI/042
81	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Split Virion)	Abnormal toxicity test	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
82	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Split Virion)	Identity	IP,2018 Vol III; Page 3633-3634
83	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Split Virion)	Physical Aspects Test	CDL/WI/003

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 7 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
84	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Inactivated Influenza Vaccine (Split Virion)	Sterility Test	CDL/WI/041 &CDL/WI/042
85	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Influenza vaccine (Surface Antigen)	Potency	IP,2018 Vol III; Page 3633-3634
86	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Influenza Vaccine (Human, Live Attenuated)	Abnormal toxicity test	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
87	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Influenza Vaccine (Human, Live Attenuated)	identity	,2018 Vol III; Page 3636-3637
88	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Influenza Vaccine (Human, Live Attenuated)	Physical Aspects test	CDL/WI/003
89	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Influenza Vaccine (Human, Live Attenuated)	Sterility test	CDL/WI/041 & CDL/WI/042
90	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Influenza Vaccine (Surface Antigen)	Potency	IP,2018 Vol III; Page 3634-3636
91	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Japanese Encephalitis Vaccine-Live	Sterility test	CDL/WI/041 & CDL/WI/042
92	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Japanese Encephalitis Vaccine-Live	Abnormal toxicity test	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
93	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Japanese Encephalitis Vaccine-Live	identity	CDL/WI/089
94	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Japanese Encephalitis Vaccine-Live	Physical Aspect test	CDL/WI/003
95	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Japanese Encephalitis Vaccine-Live	Stability test	CDL/WI/089
96	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine	Potency for Rubella Component	IP,2018 Vol III; Page 3648-49
97	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine	Potency test for Measles Component	IP,2018 Vol III; Page 3648-49

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 8 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
98	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine	Stability for Measles Component	IP,2018 Vol III; Page 3648-49
99	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine (Live)	Identity	IP, Page 3650-52 IP,2018 Page 3650-52
100	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine -Live	Abnormal Toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
101	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine -Live	Physical Aspects test	CDL/WI/003
102	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine -Live	Stability for Rubella Component	IP,2018 Vol III; Page 3648-49
103	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles & Rubella Vaccine -Live	Sterility test	CDL/WI/041 &CDL/WI/042:
104	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Mumps & Rubella (Live)	Identity	IP, Page 3650-52 IP,2018 Page 3650-52
105	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Vaccine	Potency	CDL/WI/089
106	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Vaccine -Live	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
107	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Vaccine -Live	Identity	IP,2018 Vol III; Page 3649-50
108	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Vaccine -Live	Physical Aspect Test	CDL/WI/003
109	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Vaccine -Live	Potency	IP,2018 Vol III; Page 3649-50
110	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Vaccine -Live	Stability	IP,2018 Vol III; Page 3649-50
111	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles Vaccine -Live	sterility test	CDL/WI/041 &CDL/WI/042:

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 9 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
112	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
113	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	identity	IP,2018 Page 3650-52
114	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Physical Aspect test	CDL/WI/003
115	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Potency assay of Mumps Component	IP,2018 Page 3650-52
116	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Potency for Measles Component	IP,2018 Page 3650-52
117	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Potency for Rubella Component	IP,2018 Page 3650-52
118	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Stability for Measles Component	IP,2018 Page 3650-52
119	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Stability of Mumps Component	IP,2018 Page 3650-52
120	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Stability of Rubella Component	IP,2018 Page 3650-52
121	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Measles, Mumps& Rubella Vaccine-Live	Sterility test	CDL/WI/041 &CDL/WI/042:
122	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (bOPV I & III) (Bivalent Poliomyelitis Vaccine Type I & III (Oral)	Identity	IP,2018 Vol III; Page 3681-82 SOP No. CDL/WI/098
123	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (bOPV I & III) (Bivalent Poliomyelitis Vaccine Type I & III (Oral)	Potency	IP,2018 Vol III; Page 3681-82, SOP No. CDL/WI/069
124	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (bOPV I & III) (Bivalent Poliomyelitis Vaccine Type I & III (Oral)	Stability	IP,2018 Vol III; Page 3681-82, SOP No. CDL/WI/069
125	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV 1) (Monovalent Poliomyelitis Vaccine Type 1 (Oral)	Physical Aspect Test	CDL/WI/003

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 10 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
126	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV 1) (Monovalent Poliomyelitis Vaccine Type 1 (Oral)	Potency	IP,2018 Vol III; Page 3681-82 , CDL/WI/071
127	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV 1) (Monovalent Poliomyelitis Vaccine Type 1 (Oral)	Sterility	CDL/WI/041 & CDL/WI/042
128	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV 1) (Monovalent Poliomyelitis Vaccine Type 1(Oral)	Stability	IP,2018 Vol III; Page 3681-82 , CDL/WI/071
129	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV 1) Monovalent Poliomyelitis Vaccine Type 1 (Oral)	Identity	IP,2018 Vol III; Page 3681-82 , CDL/WI/098
130	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV III) (Monovalent Poliomyelitis Vaccine Type III (Oral)	Identity	IP,2018 Vol III; Page 3681-82, SOP No.CDL/WI/098
131	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV III) (Monovalent Poliomyelitis Vaccine Type III (Oral)	Physical Aspect Test	CDL/WI/003
132	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV III) (Monovalent Poliomyelitis Vaccine Type III (Oral)	Potency	IP,2018 Vol III; Page 3681-82, SOP No. CDL/WI/073
133	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV III) (Monovalent Poliomyelitis Vaccine Type III (Oral)	Stability	IP,2018 Vol III; Page 3681-82, SOP No. CDL/WI/073
134	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Oral Polio Vaccine (mOPV III) (Monovalent Poliomyelitis Vaccine Type III (Oral)	Sterility	CDL/WI/041 & CDL/WI/042
135	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated	Identity Type-3	IP,2018 Vol III; Page 3675 SOP No. CDL/WI/074
136	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated	Identity TYPE 2	IP,2018 Vol III; Page 3675 SOP No. CDL/WI/074
137	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated)	Identity TYPE1	IP,2018 Vol III; Page 3675 SOP No. CDL/WI/074
138	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated)	Abnormal Toxicity Test	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
139	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated)	D-Antigen Content (ELISA) TYPE 3	IP,2018 Vol III; Page 3675 SOP No. CDL/WI/074

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 11 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
140	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated)	D-Antigen Content (ELISA) TYPE I	IP,2018 Vol III; Page 3675 SOP No. CDL/WI/074
141	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated)	D-Antigen Content (ELISA) TYPE2	IP,2018 Vol III; Page 3675 SOP No. CDL/WI/074
142	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated)	Physical Aspect Test	SOP No. CDL/WI/003
143	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Poliomyelitis Vaccine (Inactivated)	Sterility test	SOP No. CDL/WI/041
144	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Antiserum	Potency	IP,2018 Vol III; Page 3682, CDL/WI/134
145	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Antiserum	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
146	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Antiserum	Identity test	IP,2018 Vol III; Page 3682, CDL/WI/134
147	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Antiserum	Physical Aspect Test	CDL/WI/003
148	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Antiserum	Sterility	CDL/WI/041
149	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Vaccine Human	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
150	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Vaccine Human	Identity test	IP,2018 Vol III;Page 3684-86
151	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Vaccine Human	Physical Aspect Test	CDL/WI/003
152	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Vaccine Human	Potency	IP,2018 Vol III; Page 3684-86
153	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Vaccine Human	Stability	IP,2018 Vol III; Page 3684-86

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 12 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
154	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rabies Vaccine Human	Sterility	CDL/WI/041
155	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rotavirus Vaccine (Oral)	Physical Aspect Test	CDL/WI/003
156	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rubella Vaccine	Abnormal toxicity test	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
157	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rubella Vaccine	identity	IP,2018 Vol III; Page 3689-91
158	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rubella Vaccine	Physical aspect test	CDL/WI/003:
159	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rubella Vaccine	Stability	IP,2018 Vol III; Page 3689-91
160	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rubella Vaccine -Live	Potency	IP,2018 Vol III; Page 3689-91
161	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Rubella Vaccine(Live)	Sterility test	SOP No. CDL/WI/041
162	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
163	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Identity Test	IP,2018 Vol III; Page 3692
164	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Physical Aspect Test	CDL/WI/003
165	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Potency (Cobra Venom)	IP,2018 Vol III; Page3692
166	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Potency (Echis Venom)	IP,2018 Vol III; Page3692
167	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Potency (Krait Venom)	IP,2018 Vol III; Page3692

SCOPE OF ACCREDITATION

Laboratory Name :	CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA		
Accreditation Standard	ISO/IEC 17025:2017		
Certificate Number	TC-5586	**Page No**	13 of 22
Validity	08/08/2021 to 07/08/2023	**Last Amended on**	18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
168	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Potency (Russell Viper Venom)	IP,2018 Vol III; Page3692
169	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Snake Venom Antiserum	Sterility	CDL/WI/041
170	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Antitoxin	Potency	IP,2018 Page Page 3692-93
171	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus antitoxin	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
172	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Antitoxin	Identity test	IP,2018 , Vol III Page 3692-93
173	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Antitoxin	Physical Aspect Test	CDL/WI/003
174	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Antitoxin	Sterility	CDL/WI/041
175	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Vaccine (adsorbed)	Identity test	IP 2018 Vol III; Page 3694-3695 Vol I; Clause 2.2.14 Page 67-68 & 71-72
176	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Vaccine (adsorbed)	Limes Flocculation	IP 2018 Vol I; Clause 2.2.16 Page 71-72
177	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Vaccine (adsorbed)	Physical Aspect	CDL/WI/003
178	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Vaccine (adsorbed)	Potency 'T' Component (by Antibody Induction method)	IP 2018 Vol III; Page 3695-3696 Vol III; Page 3692-3693
179	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Vaccine (adsorbed)	Potency 'T' Component (by Lethal Challenge method in mice)	IP 2018 Vol III; Page 3695-3696
180	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Vaccine (adsorbed)	Specific toxicity test	IP 2018 Vol III; Page 3694
181	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Tetanus Vaccine (adsorbed)	Sterility	CDL/WI/041

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 14 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
182	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	Abnormal Toxicity Test	IP 2018 Vol III; Page 3706 Vol I; Clause 2.2.1 Page 27
183	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	Identity Test	IP 2018 Vol III; Page 3706 Vol I; Clause 2.2.14 Page 67-68
184	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	Physical Aspect Test	CDL/WI/003
185	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	Sterility	CDL/WI/041
186	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Vi Conjugate Vaccine	Abnormal Toxicity Test	IP 2018 Vol III; Page 3711 Vol I; Clause 2.2.1 Page 27
187	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Vi Conjugate Vaccine	c) Physical Aspect Test	SOP No. CDL/WI/003
188	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Vi Conjugate Vaccine	d) Identification	IP 2018 Vol III; Page 3710 Vol I; Clause 2.2.14 Page 67-68
189	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Typhoid Vi Conjugate Vaccine	Sterility	SOP No. CDL/WI/041
190	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Yellow fever Vaccine-live	Abnormal toxicity	IP 2018 Vol III; Page 3711Vol I; Clause 2.2.1 Page 27
191	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Yellow fever Vaccine-live	Identity	IP,2018 Vol III; Page 3715-18
192	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Yellow fever Vaccine-live	Physical Aspects Test	CDL/WI/003
193	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Yellow fever Vaccine-live	Potency	IP,2018 Vol III; Page 3715-18
194	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Yellow fever Vaccine-live	Stability	IP,2018 Vol III; Page 3715-18
195	BIOLOGICAL-BIOLOGICALS DERIVED PHARMACEUTICALS	Yellow fever Vaccine-live	Sterility test	CDL/WI/041 & CDL/WI/042

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 15 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
196	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Rabies Serum	Protein	IP Page 3682 Clause 2.3.49 Page 165
197	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Rabies Serum	Cresol	SOP No. CDL/WI/068 Ed-04
198	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Rabies Serum	Cresol	SOP No. CDL/WI/068 Ed-04
199	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Rabies Serum	pH	IP Page 3682 Clause 2.4.24 Page 215-216
200	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Rabies Serum	Phenol	IP Page 3682 Clause 2.3.36 Page 151
201	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Rabies Serum	Phenol	IP, Page 3682 Clause 2.3.36 Page 151
202	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Rabies Serum	Protein	IP ,Page 3682 Clause 2.3.49 page 165
203	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	Cresol	SOP No. CDL/WI/068 Ed-04
204	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	Cresol	SOP No. CDL/WI/068 Ed-04 : 2019
205	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	pH	IP , Page 3692 Clause 2.4.24 Page 215-216
206	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	Phenol	IP Page 3692 Clause 2.3.36 Page 151
207	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	Phenol	IP, Page 3692 Clause 2.3.36 Page 151
208	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	Protein	IP Page 3692 Clause 2.3.49 Page 165
209	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	Protein	IP Page 3692 Clause 2.3.49 Page 165
210	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti Snake Venom Serum (Freeze Dried)	Volume	IP Vol II Page No.1115
211	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-Rabies Vaccine (Cell Culture)	Moisture	IP, Page 3682-3686 Clause 2.3.43 Page 156
212	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-Rabies Vaccine (Cell Culture)	Moisture	IP, Page 3682-3686 Clause 2.3.43 Page 156
213	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-Rabies Vaccine (Cell Culture)	pH	IP, Page 3682-3686 Clause 2.4.24 Page 215-216
214	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-Rabies Vaccine (Cell Culture)	Thiomersal	IP, Page 3682-3686 Clause 2.3.48 Page 165, Method A

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 16 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
215	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-Rabies Vaccine (Cell Culture)	Volume	IP, Vol II Page No. 1115
216	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-Rabies Vaccine (Cell Culture)	Volume	IP, Vol II Page No. 1115
217	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-snake Venom serum	Cresol	SOP No. CDL/WI/068 Ed-04 Dt 01-05-2019
218	CHEMICAL- DRUGS & PHARMACEUTICALS	Anti-snake Venom serum	Moisture	IP Page 3570,3692 Clause 2.3.43 Page 156
219	CHEMICAL- DRUGS & PHARMACEUTICALS	Bacillus Calmette Guerin Vaccine (Freeze Dried)	Volume	IP Vol II Page No.1115
220	CHEMICAL- DRUGS & PHARMACEUTICALS	bOPV Bivalent Poliomyelitis I &III (Oral)	Volume	IP Vol II Page No.1115
221	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria & Tetanus Vaccine	Aluminium	IP, Page 3599-3600 Clause 2.3.9 Page 138, Method B
222	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria & Tetanus Vaccine	Formalin	IP, Page 3599-3600 Clause 2.3.20 Page 141, Method B
223	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria & Tetanus Vaccine	pH	IP Page 3599-3600 Clause 2.4.24 Page 215-216
224	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria & Tetanus Vaccine	Thiomersal	IP Page 3599-3600 Clause 2.3.48 Page 165, Method A
225	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria & Tetanus Vaccine	Thiomersal	IP Page 3599-3600 Clause 2.3.48 Page 165, Method A
226	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria & Tetanus Vaccine	Volume	IP Vol II Page No. 1115
227	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria & Tetanus Vaccine	Volume	IP, Vol II Page No. 1115
228	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria , Pertussis Tetanus Vaccine (whole cell), Hepatitis B (r DNA), Heamophilus Type b Conjugate (Adsorbed) & Poliomyelitis Vaccine	Aluminum	IP, Page 3599-3600 Clause 2.3.9 Page 138, Method B: 2018
229	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria , Pertussis, Tetanus Vaccine (whole cell), Hepatitis - B (rDNA), Haemophilus Type-B Conjugate (adsorbed) & Poliomyeliyis Vaccine	pH	IP Page 3598-3599 Clause 2.4.24 Page 215-216: 2018
230	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria , Pertussis, Tetanus Vaccine (whole cell), Hepatitis - B(rDNA), Heamophilus Type- b Conjugate (adsorbed) & Pliomyelitis vaccine	Volume	IP,2018 Vol II Page No.1115
231	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria , Pertussis, Tetanus Vaccine (whole cell), Hepatitis - B(rDNA), Heamophilus Type- b Conjugate (adsorbed) & Poliomyelitis vaccine	2-Phenoxyethanol	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 17 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
232	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria , Pertussis, Tetanus Vaccine (whole cell), Hepatitis - B(rDNA), Heamophilus Type- b Conjugate (adsorbed) & Poliomyelitis vaccine	2-Phenoxyethanol	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019
233	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria Antitoxin	Cresol	SOP No. CDL/WI/068 Ed-04
234	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria Antitoxin	pH	IP, Page 3598-3599 Clause 2.4.24 Page 215-216
235	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria Antitoxin	Phenol	IP, Page 3598-3599 Clause 2.3.36 Page 151
236	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria Antitoxin	Protein	IP, Page 3598-3599 Clause 2.3.49 Page 165
237	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria Antitoxin	Volume	IP, Vol II Page No. 1115
238	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertusis & Tetanus Vaccine	Aluminium	IP, Page 3602-3604 Clause 2.3.9 Page 138, Method B
239	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertusis & Tetanus Vaccine	Thiomersal	IP, Page 3602-3604 Clause 2.3.48 Page 165, Method A
240	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertusis & Tetanus Vaccine	Thiomersal	IP,Page 3602-3604 Clause 2.3.48 Page 165, Method A
241	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertusis & Tetanus Vaccine	Volume	IP, Vol II Page No. 1115
242	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis & Tetanus Vaccine	pH	IP, Page 3602-3604 Clause 2.4.24 Page 215-216
243	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis & Tetanus Vaccine	Volume	IP, Vol II Page No. 1115
244	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis &Tetanus Vaccine	Formalin	IP Page 3602-3604 Clause 2.3.20 Page 141, Method B
245	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Aluminium	IP Page 3609-3612 Clause 2.3.9 Page 138, Method B
246	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Aluminium	IP, Page 3609-3612 Clause 2.3.9 Page 138, Method B
247	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Formalin	IP, Page 3609-3612 Clause 2.3.20 Page 141, Method B
248	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	pH	IP, Page 3609-3612 Clause 2.4.24 Page 215-216
249	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Thiomersal	IP, Page 3609-3612 Clause 2.3.48 Page 165, Method A

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 18 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
250	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Volume	IP, Vol II Page No. 1115
251	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Volume	IP, Vol II Page No. 1115
252	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Hepatitis B Vaccine (Adsorbed)	Aluminium	IP, 2018 Page 3607-3609 Clause 2.3.9 Page 138, Method B
253	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Hepatitis B Vaccine (Adsorbed)	Formalin	IP, Page 3607-3609 Clause 2.3.20 Page 141, Method B
254	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Hepatitis B Vaccine (Adsorbed)	pH	IP, Page 3607-3609 Clause 2.4.24 Page 215-216
255	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Hepatitis B Vaccine (Adsorbed)	Thiomersal	IP, Page 3607-3609 Clause 2.3.48 Page 165, Method A
256	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) & Hepatitis B Vaccine (Adsorbed)	Volume	IP, Vol II Page No. 1115
257	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Aluminium	IP, Page 3604-3607 Clause 2.3.9 Page 138, Method B
258	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Aluminium	IP, Page 3604-3607 Clause 2.3.9 Page 138, Method B
259	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Formalin	IP, Page 3604-3607 Clause 2.3.20 Page 141, Method B
260	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	pH	IP, Page 3604-3607 Clause 2.4.24 Page 215-216
261	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Thiomersal	IP, Page 3604-3607 Clause 2.3.48 Page 165, Method A
262	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Thiomersal	IP, Page 3604-3607 Clause 2.3.48 Page 165, Method A
263	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Volume	IP, Vol II Page No. 1115
264	CHEMICAL- DRUGS & PHARMACEUTICALS	Diphtheria, Pertussis, Tetanus (Whole Cell) Hepatitis B (rDNA) & Haemophilus Type -b Conjugate Vaccine (Adsorbed)	Volume	IP,2018 Vol II Page No. 1115

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 19 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
265	CHEMICAL- DRUGS & PHARMACEUTICALS	Haemophilus Type -b Conjugate Vaccine (Freeze Dried)	pH	IP page 3621-3624 Clause 2.4.24 Page 215-216
266	CHEMICAL- DRUGS & PHARMACEUTICALS	Haemophilus Type -b Conjugate Vaccine (Freeze Dried)	Thiomersal	IP Page3621-3624 Clause 2.3.48 Page 165 Method A
267	CHEMICAL- DRUGS & PHARMACEUTICALS	Haemophilus Type -b Conjugate Vaccine (Freeze Dried)	Volume	IP Vol II 1115
268	CHEMICAL- DRUGS & PHARMACEUTICALS	Hepatitis A Vaccine (Inactivated)	2-Phenoxyethanol	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019
269	CHEMICAL- DRUGS & PHARMACEUTICALS	Hepatitis A Vaccine (Inactivated)	Formalin	IP page 3628-3630 clause 2.3.20 Page 141 Method B
270	CHEMICAL- DRUGS & PHARMACEUTICALS	Hepatitis A Vaccine (Inactivated)	pH	IP Page 3628-3630 Clause 2.4.24 Page 215-216
271	CHEMICAL- DRUGS & PHARMACEUTICALS	Hepatitis B Vaccine (rDNA)	Aluminium	IP, Page 3625-3628 Clause 2.3.9 Page 138, Method B
272	CHEMICAL- DRUGS & PHARMACEUTICALS	Hepatitis B Vaccine (rDNA)	Thiomersal	IP, Page 3625-3628 Clause 2.3.48 Page 165, Method A
273	CHEMICAL- DRUGS & PHARMACEUTICALS	Inactivated Poliomyelitis Vaccine	2-Phenoxyethanol	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019
274	CHEMICAL- DRUGS & PHARMACEUTICALS	Inactivated Poliomyelitis Vaccine	Formalin	IP, Page 3672-3676 Clause 2.3.20 Page 141, Method B
275	CHEMICAL- DRUGS & PHARMACEUTICALS	Inactivated Poliomyelitis Vaccine	pH	IP, Page 3672-3676 Clause 2.4.24 Page 215-216
276	CHEMICAL- DRUGS & PHARMACEUTICALS	Inactivated Poliomyelitis Vaccine	Volume	IP, Vol II Page No. 1115
277	CHEMICAL- DRUGS & PHARMACEUTICALS	Japanese Encephalitis Vaccine (Inactivated)	2-Phenoxyethanol	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019
278	CHEMICAL- DRUGS & PHARMACEUTICALS	Japanese Encephalitis Vaccine (Inactivated)	Aluminum	IP, Page 3645-3647 Clause 2.3.9 Page 138, Method B
279	CHEMICAL- DRUGS & PHARMACEUTICALS	Japanese Encephalitis Vaccine (Inactivated)	Formalin	IP, Page 3645-3647 Clause 2.3.20 Page 141, Method B
280	CHEMICAL- DRUGS & PHARMACEUTICALS	Japanese Encephalitis Vaccine (Inactivated)	pH	IP, Page 3645-3647Clause 2.4.24 Page 215-216
281	CHEMICAL- DRUGS & PHARMACEUTICALS	Japanese Encephalitis Vaccine (Inactivated)	Thiomersal	IP, Page 3645-3647 Clause 2.3.48 Page 165, Method A
282	CHEMICAL- DRUGS & PHARMACEUTICALS	Japanese Encephalitis Vaccine (Inactivated)	Volume	IP, Page 3645-3647 Clause 2.3.48 Page 165, Method A
283	CHEMICAL- DRUGS & PHARMACEUTICALS	Measles & Rubella Vaccine	Moisture	IP, Page 3682-3686 Clause 2.3.43 Page 156

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 20 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
284	CHEMICAL- DRUGS & PHARMACEUTICALS	Measles & Rubella Vaccine (live)	Moisture	IP, Page 3682-3686 Clause 2.3.43 Page 156
285	CHEMICAL- DRUGS & PHARMACEUTICALS	Measles Vaccine (live)	Moisture	IP, Page 3682-3686 Clause 2.3.43 Page 156
286	CHEMICAL- DRUGS & PHARMACEUTICALS	Measles, Mumps & Rubella Vaccine (Live)	Moisture	IP, Page 3682-3686 Clause 2.3.43 Page 156
287	CHEMICAL- DRUGS & PHARMACEUTICALS	Meningococcal Vaccine (Freeze Dried)	Aluminium	IP,2018 Page 3625-3628 Clause 2.3.9 Page 138, Method B
288	CHEMICAL- DRUGS & PHARMACEUTICALS	Meningococcal Vaccine (Freeze Dried)	Moisture	IP, Page 3669-3672 Clause 2.3.43 Page 156
289	CHEMICAL- DRUGS & PHARMACEUTICALS	Meningococcal Vaccine (Freeze Dried)	pH	IP,2018 Page 3669-3672 Clause 2.4.24 Page 215-216
290	CHEMICAL- DRUGS & PHARMACEUTICALS	Meningococcal Vaccine (Freeze Dried)	Thiomersal	IP, Page 3669-3672 Clause 2.3.48 Page 165, Method A
291	CHEMICAL- DRUGS & PHARMACEUTICALS	Meningococcal Vaccine (Freeze Dried)	Volume	IP Vol II Page No.1115
292	CHEMICAL- DRUGS & PHARMACEUTICALS	Oral polio Vaccine (m-OPV-1)	Volume	IP, Vol II Page No. 1115
293	CHEMICAL- DRUGS & PHARMACEUTICALS	Oral Polio Vaccine (mOpv Type-III)	Volume	IP, Vol II Page No. 1115
294	CHEMICAL- DRUGS & PHARMACEUTICALS	Pneumococcal Polysaccharide Vaccine	2-Phenoxyethanol	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019
295	CHEMICAL- DRUGS & PHARMACEUTICALS	Pneumococcal Polysaccharide Vaccine	pH	IP, Page 3704-3706 Clause 2.4.24 Page 215-216
296	CHEMICAL- DRUGS & PHARMACEUTICALS	Pneumococcal Polysaccharide Vaccine	Phenol	IP,2018 Page 3704-3706 Clause 2.3.36 Page 151
297	CHEMICAL- DRUGS & PHARMACEUTICALS	Pneumococcal Polysaccharide Vaccine	Volume	IP, Vol II Page No. 1115
298	CHEMICAL- DRUGS & PHARMACEUTICALS	Pneumococcal Polysaccharide Vaccine	Volume	IP,2018 Vol II Page No. 1115
299	CHEMICAL- DRUGS & PHARMACEUTICALS	Poliomyelitis Vaccine Inactivated	Volume	IP Vol II page No.1115
300	CHEMICAL- DRUGS & PHARMACEUTICALS	Rota virus Vaccine (Oral)	Moisture	IP, Page 3682-3686 Clause 2.3.43 Page 156
301	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Antitoxin	Cresol	SOP No. CDL/WI/068 Ed-04 Dt 01-05-2019

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 21 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
302	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Antitoxin	pH	IP Page 3692-3693 Clause 2.4.24 Page 215-216
303	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Antitoxin	Phenol	IP Page 3692-3693 Clause 2.3.36 Page 151
304	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Antitoxin	Protein	IP Page 3692-3693 Clause 2.3.49 Page 165
305	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Antitoxin	Protien	IP Page 3692-3693 Clause 2.3.49 Page 165
306	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Antitoxin	Volume	IP , Vol II Page No. 1115
307	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	Aluminium	IP, Page 3693-3699 Clause 2.3.9 Page 138, Method B
308	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	Formailn	IP, Page 3693-3699 Clause 2.3.20 Page 141, Method B
309	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	pH	IP,2018 Page 3693-3699 Clause 2.4.24 Page 215-216
310	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	Thiomersal	IP, 2018 Page 3693-3699 Clause 2.3.48 Page 165, Method A
311	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	Thiomersal	IP, 2018 Page 3693-3699 Clause 2.3.48 Page 165, Method A
312	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	Volume	IP,2018 Vol II Page No. 1115
313	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	Volume	IP,2018 Vol II Page No. 1115
314	CHEMICAL- DRUGS & PHARMACEUTICALS	Tetanus Vaccine	Volume	IP,2018 Vol II Page No. 1115
315	CHEMICAL- DRUGS & PHARMACEUTICALS	Typhoid Conjugate Vaccine	2 Phenoxyethanol	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019: 2019
316	CHEMICAL- DRUGS & PHARMACEUTICALS	Typhoid Conjugate Vaccine	2-Phenoxyethanol SOP No.	SOP No. CDL/WI/117 Ed-04 Dt 01-05-2019: 2019
317	CHEMICAL- DRUGS & PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	pH	IP,2018 Page 3704-3706 Clause 2.4.24 Page 215-216
318	CHEMICAL- DRUGS & PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	Phenol	IP,2018 Page 3704-3706 Clause 2.3.36 Page 151
319	CHEMICAL- DRUGS & PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	Volume	IP,2018 Vol II Page No. 1115

SCOPE OF ACCREDITATION

Laboratory Name : CENTRAL DRUGS LABORATORY, CENTRAL RESEARCH INSTITUTE, KASAULI, SOLAN, HIMACHAL PRADESH, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-5586 **Page No** 22 of 22

Validity 08/08/2021 to 07/08/2023 **Last Amended on** 18/10/2021

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
320	CHEMICAL- DRUGS & PHARMACEUTICALS	Typhoid Polysaccharide Vaccine	Volume	IP,2018 Vol II Page No. 1115
321	CHEMICAL- DRUGS & PHARMACEUTICALS	Yellow Fever Vaccine	Volume	IP, Vol II Page No. 1115
322	CHEMICAL- DRUGS & PHARMACEUTICALS	Yellow Fever Vaccine	Volume	IP, Vol II Page No. 1115